Safely Skip PET2 After Brentuximab in Hodgkin Lymphoma? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
"We are thankfully starting to be blessed with more options than we ve ever had," but "in the frontline proliferative setting, ruxolitinib has remained the standard of care."
Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.